




Active substances set

Search phrase: Acute myeloid leukemia

Below you will find a list of active substances registered by the European Medical Agency (EMA) in the last 15 years, recommended by the European Society of Clinical Oncology (ESMO) and their reimbursement status in the country.



Gemtuzumab ozogamicin	Gemtuzumab Ozogamicin is indicated for combination therapy with daunorubicin (DNR) and cytarabine (AraC) for the treatment of patients aged 15 years and above with previously untreated, de novo CD33-positive acute myeloid leukaemia (AML), except acute promyelocytic leukaemia (APL).	©	FULL REIMBURSEMENT ESMO
Daunorubicin / cytarabine	Daunorubicin / Cytarabine is indicated for the treatment of adults with newly diagnosed, therapy-related acute myeloid leukaemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC).		FULL REIMBURSEMENT ESMO
Gilteritinib	Gilteritinib is indicated as monotherapy for the treatment of adult patients who have relapsed or refractory acute myeloid leukaemia (AML) with a FLT3 mutation.		FULL REIMBURSEMENT ESMO
Venetoclax	Venetoclax in combination with a hypomethylating agent is indicated for the treatment of adult patients with newly diagnosed acute myeloid leukaemia (AML) who are ineligible for intensive chemotherapy.		FULL REIMBURSEMENT ESMO
lvosidenib	lvosidenib in combination with azacitidine is indicated for the treatment of adult patients with newly diagnosed acute myeloid leukaemia (AML) with an isocitrate dehydrogenase- 1 (IDH1) R132 mutation who are not eligible to receive standard induction chemotherapy .	 <th>FULL REIMBURSEMENT ESMO</th>	FULL REIMBURSEMENT ESMO